MX2024013482A - Composiciones de receptor de celulas t en multiplex, terapias combinadas, y sus usos - Google Patents

Composiciones de receptor de celulas t en multiplex, terapias combinadas, y sus usos

Info

Publication number
MX2024013482A
MX2024013482A MX2024013482A MX2024013482A MX2024013482A MX 2024013482 A MX2024013482 A MX 2024013482A MX 2024013482 A MX2024013482 A MX 2024013482A MX 2024013482 A MX2024013482 A MX 2024013482A MX 2024013482 A MX2024013482 A MX 2024013482A
Authority
MX
Mexico
Prior art keywords
multiplexed
cell receptor
combination therapies
receptor compositions
compositions
Prior art date
Application number
MX2024013482A
Other languages
English (en)
Spanish (es)
Inventor
Yifan Wang
Cagan Gurer
Gavin Macbeath
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of MX2024013482A publication Critical patent/MX2024013482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
MX2024013482A 2022-05-02 2024-10-31 Composiciones de receptor de celulas t en multiplex, terapias combinadas, y sus usos MX2024013482A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263337522P 2022-05-02 2022-05-02
US202263342451P 2022-05-16 2022-05-16
US202263413553P 2022-10-05 2022-10-05
US202263423269P 2022-11-07 2022-11-07
PCT/US2023/020338 WO2023215183A1 (en) 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof

Publications (1)

Publication Number Publication Date
MX2024013482A true MX2024013482A (es) 2024-12-06

Family

ID=88646870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013482A MX2024013482A (es) 2022-05-02 2024-10-31 Composiciones de receptor de celulas t en multiplex, terapias combinadas, y sus usos

Country Status (12)

Country Link
US (1) US20250288675A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516264A (cg-RX-API-DMAC7.html)
KR (1) KR20250006149A (cg-RX-API-DMAC7.html)
CN (1) CN119487060A (cg-RX-API-DMAC7.html)
AU (1) AU2023265422A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248253A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024016274A2 (cg-RX-API-DMAC7.html)
IL (1) IL316250A (cg-RX-API-DMAC7.html)
MX (1) MX2024013482A (cg-RX-API-DMAC7.html)
TW (1) TW202406569A (cg-RX-API-DMAC7.html)
WO (1) WO2023215183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005746A (es) * 2021-11-10 2024-07-19 Tscan Therapeutics Inc Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113595A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS

Also Published As

Publication number Publication date
EP4519305A1 (en) 2025-03-12
KR20250006149A (ko) 2025-01-10
IL316250A (en) 2024-12-01
CN119487060A (zh) 2025-02-18
EP4519305A4 (en) 2026-05-06
TW202406569A (zh) 2024-02-16
JP2025516264A (ja) 2025-05-27
WO2023215183A1 (en) 2023-11-09
CA3248253A1 (en) 2023-11-09
US20250288675A1 (en) 2025-09-18
CO2024016274A2 (es) 2024-12-09
AU2023265422A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
WO2019183359A8 (en) Methods and compositions for molecular authentication
MX2025003235A (es) Composiciones y metodos para el suministro de proteinas de membrana
AU2020337417A8 (en) Organoid mesoderm lineage diversification
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
MX2010006576A (es) Composiciones y metodos para producir isopreno.
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2024073723A3 (en) Anti-cd122 antibodies and uses thereof
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MX2023010969A (es) Edicion multiplex con enzimas cas.
MX2022015801A (es) Sistemas de expresion de baculovirus.
EP4280806A3 (en) Efficient multicast
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
WO2021248023A3 (en) Compositions and methods for epigenome editing
WO2023141478A3 (en) Cytokine-immunoreceptor fusion proteins and uses thereof
WO2023081455A3 (en) Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same
MX2025013242A (es) Quinoxalinas sustituidas
MX2025000236A (es) Composiciones para el tratamiento de hipertension
CO2024016274A2 (es) Composiciones de receptor de células t en multiplex, terapias combinadas, y sus usos
BR112021024952A2 (pt) Composições de liberação sustentada de alfa-cetoglutarato
WO2023014908A8 (en) Lpar1 antagonists and uses thereof
MX2025008767A (es) Compuestos triciclicos sustituidos
MX2023007629A (es) Muteinas de il-2 para el tratamiento contra enfermedades autoinmunitarias e inflamatorias.
NZ580465A (en) A spacer that limits compression of an insulator
WO2021067664A3 (en) Methods for targeted cell depletion